Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

Stock Information for NanoVibronix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NanoVibronix Inc.

Immuron New U.S. Department of Defense Award & Clinical Trial Update
Immuron IMM-529 IND approved by FDA
Immuron Announces Clinical Trial Update
Presenting on Emerging Growth Conference 87 Day 1 on October 22. Register to live stream.
Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target
Immuron Q1 FY26 YoY growth
Immuron Submits IMM-529 IND to FDA
Immuron Letter to Shareholders - Projects Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.